Heart Failure With Reduced Ejection Fraction
Cardiovascular·MeSH: Heart Failure
Prevalence
1800.0 / 100K
Incidence
300.0 / 100K/yr
8 drugs in development·3 companies·6 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| CardiAMP® | BioCardia, Inc. (BCDA) |
Phase 2(1)
| Drug | Company |
|---|---|
| danicamtiv | MyoKardia, Inc. (MYOK) |
Unknown(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Heart Failure With Reduced Ejection Fraction?
BioSniper tracks 8 drugs in development for Heart Failure With Reduced Ejection Fraction across 3 companies.
How many clinical trials target Heart Failure With Reduced Ejection Fraction?
There are 6 clinical trials targeting Heart Failure With Reduced Ejection Fraction tracked by BioSniper.
What is the prevalence of Heart Failure With Reduced Ejection Fraction?
The estimated prevalence of Heart Failure With Reduced Ejection Fraction is approximately 1800.0 per 100,000 population.
Deep-dive into Heart Failure With Reduced Ejection Fraction
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis